AMN Healthcare swings to $116.2 million Q2 loss on $128 million impairment charges
AMN Healthcare reported second-quarter 2025 revenue of $658 million, down 11% from a year earlier, and a net loss of $116.2 million, or $3.02 per diluted share, after $128 million in noncash goodwill and intangible asset impairment charges. Management said clients slowed decision-making amid an uncertain healthcare policy environment, and third-quarter revenue guidance of $610 million to $625 million is 9% to 11% below the prior year, so shareholders face both a sharp profit decline and a weaker near-term revenue outlook.
Key points
- Q2 2025 revenue was $658 million, down 11% from $740.7 million in Q2 2024.
- Net loss was $116.2 million, or $3.02 per diluted share, versus net income of $16.2 million, or $0.42 per diluted share, a year earlier.
- Adjusted diluted EPS was $0.30, compared with $0.98 in the second quarter of 2024.
- Third-quarter 2025 revenue is guided to $610 million to $625 million, 9% to 11% lower than the prior year.
The filing
Written by AI on Nov 8, 2026, 6:58 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.